Media about us

• NovaMedica Innotech R&D center meets Russian GMP standards

  28 December 2017 GMP News

  

  NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the conclusion of the Russian Ministry of Industry and Trade on the compliance of the production site of NovaMedica Innotech R&D center, a subsidiary of NovaMedica, with the Russian Good Manufacturing Practice (GMP) standards.

• Authorities approve the application of NovaMedica for a new production facility

  26 December 2017 GMP News

  

  NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the approval of the Inter-Agency Commission for conclusion of Special Investment Contract (SPIC) under the investment project aimed at establishing a pharmaceutical plant for sterile injectable drugs in the Kaluga region.

• Contract pharmaceutical manufacturing sites in Russia are very relevant

  27 November 2017 GMP News

  

  A round table on Contract Manufacturing of Pharmaceutical Products was held on November 22, 2017, at Pharmtech & Ingredients 2017, the 19th international exhibition of equipment, raw materials and technologies for pharmaceutical manufacturing. The event moderator was Alexander Kuzin, the General Director at NovaMedica. 

• Contract R&D market is developing in Russia

  23 October 2017 GMP News

  

  NovaMedica has launched in Moscow its R&D Center for development of new drug products. The Center is going to become attractive R&D site for customized developments and contract manufacturing.

• Russian pharmaceutical map has a new point of convergence

  23 October 2017 GMP News

  

  An interesting international pharmaceutical project has started in Russia. This project is a result of a convergence of interests of Rusnano, Russian state investment corporation, Domain Associates, an American venture capital foundation, and Pfizer, an American pharmaceutical corporation.  

• NovaMedica receives a license for production site at its R&D center

  20 October 2017 GMP News

  

  NovaMedica received a license from the FBI SID & GP for a pilot production site at its R&D center. This was announced by Alexander Kuzin, the General Director of the company.

• India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

  20 September 2017 Joseph Keenan / Fierce Pharma

  

  Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation. The Russians have been pressuring foreign pharmaceutical companies to engage in local production if they want to be in its market. Earlier this year, Russia-based NovaMedica announced it began work on a new plant in Russia’s Kaluga region where it will produce 30 of Pfizer’s sterile injected generic medications for the local market.

• New 30-minute STI test allows just one clinic trip

  08 September 2017 Helen Clark / Gears of Biz

  

  A new speedy test will mean that for the first time ever patients with common sexually-transmitted infections will be able to get their diagnosis and treatment in one clinical visit. The test works by placing a swab or a small amount of urine into a test cartridge, which is then inserted into the diagnostic machine, which has been designed by innovation firm Atlas Genetics Ltd.

• Roche to up Russian Gazyva supply through local fill/finish deal

  07 September 2017 Dan Stanton / BioPharma Reporter.com

  

  Local manufacturer Pharmstandard will make the finished dosage form of Roche’s monoclonal antibody Gazyva (obinutuzumab) at its site in Ufa. The policy has driven most multinationals to sign contracts with domestic drugmakers and invest in local joint ventures. Pfizer broke ground on a facility with NovaMedica in Kaluga in May, GSK formed a JV with Binnopharm in 2011, while AstraZeneca , Novartis and Novo Nordisk have all invested in Russian production facilities.

• Prostate Cancer: Epic Sciences AR-V7 Test

  17 August 2017 OncLive

  

  Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center share their views on the Epic Sciences AR-V7 test in development for prostate cancer.